Does long-term Ozempic use cause more harm than good?

What did @thebalanced.brunette actually say?

She says she was on Ozempic for about a year, stopped two months ago, went in for a checkup, and walked out with a diagnosis of osteoporosis and osteopenia. Her conclusion: "that's what happens if you Ozempic for weight loss and you lose too much weight." She's attributing significant bone loss directly to Ozempic use after one year on the medication. That's a specific, alarming causal claim, and it deserves a careful look rather than a reflexive share.

To be clear, she's describing a real medical diagnosis from what sounds like a real clinical visit. This isn't someone speculating. But the leap from "I took Ozempic, I lost weight, I now have bone loss" to "Ozempic caused my osteoporosis" is not as straightforward as the framing suggests.

Does the science back this up?

Partially, but the picture is more complicated than the video implies. Rapid, significant weight loss, from any cause, is a well-documented driver of bone density reduction. The issue isn't unique to GLP-1 medications.

A 2023 paper by Bikou et al. in Obesity Reviews found that semaglutide-associated weight loss does correlate with reductions in bone mineral density, particularly in people who lose weight rapidly without adequate resistance training or protein intake. However, the same research noted this pattern appears with all obesity interventions that produce rapid weight loss, including bariatric surgery and very low calorie diets. Semaglutide is not uniquely toxic to bone.

Separately, a 2022 study by Niu et al. in Frontiers in Endocrinology looked at GLP-1 receptor agonists and bone metabolism directly. They found that GLP-1 receptors are expressed in osteoblasts, and that GLP-1 agonists may actually have a modest bone-protective effect at the cellular level. The clinical picture is complicated by the fact that weight loss itself reduces mechanical load on the skeleton, which can reduce bone density regardless of what caused the weight loss.

One year of use is also a short timeline to develop clinically significant osteoporosis unless there were underlying risk factors already present.

What did they get wrong (or right)?

She got the association roughly right but the causation wrong, or at least oversimplified it. Bone density loss following significant weight loss is real and documented. What she's presenting as an Ozempic-specific danger is more accurately a rapid-weight-loss danger that applies to multiple interventions.

What she likely got wrong is attributing the bone loss primarily to the drug rather than to the weight loss itself, and potentially to pre-existing risk factors. Developing osteoporosis after one year on a medication, with no mention of baseline bone density testing before starting, is a significant gap in the causal story she's telling. Did she have a DEXA scan before starting Ozempic? Was she getting adequate calcium and vitamin D? Was she doing resistance training? None of that is addressed.

She also makes no distinction between osteopenia, which is reduced bone density, and osteoporosis, which is a more serious condition. She seems to have both, which is unusual from a single year of weight loss alone and raises questions about her baseline status.

To her credit, she's raising a real concern that clinicians should be discussing with patients before starting GLP-1 therapy, particularly in women and older adults.

What should you actually know?

If you are on or considering a GLP-1 medication for weight loss, bone health is a legitimate conversation to have with your prescriber, but it should start with a baseline DEXA scan, not alarm after the fact. The risk is not zero, but it is not unique to Ozempic.

Key things to discuss with a clinician: your baseline bone mineral density, your calcium and vitamin D levels, whether you are doing resistance-bearing exercise, and how quickly you are losing weight. The rate of weight loss matters significantly. Losing weight slowly with adequate protein and resistance training appears to preserve more lean mass and bone density than rapid loss.

Anyone with additional risk factors for osteoporosis, including female sex, family history, low body weight at baseline, or prior fractures, should be especially proactive about this conversation. The framing in this video treats bone loss as an inevitable Ozempic consequence. It is not. It is a manageable risk that requires monitoring.